Literature DB >> 2140993

Follicular and luteal cysts after treatment with gonadotropin-releasing hormone analog for in vitro fertilization.

Z Ben-Rafael1, D Bider, Y Menashe, R Maymon, M Zolti, S Mashiach.   

Abstract

Ovarian cysts are a common complication of GnRH-a administration. We followed 98 patients who were suppressed with GnRH-a before ovarian stimulation with hMG for IVF treatment. Approximately 20% of the patients receiving GnRH-a during the follicular or luteal phase had developed ovarian cysts. However, the number of cysts per patient was significantly higher in the follicular phase compared with luteal phase. Systematic aspiration of those cysts under local anesthesia permitted the start of ovarian stimulation with hMG as scheduled on day 16 after GnRH-a administration. Follicular fluid content of the cysts revealed similar levels of steroids to those in normal follicles. These cysts contained few cells and no egg. In vitro fertilization treatment was more successful in patients whose cysts were aspirated during the luteal phase than in those with cysts during the follicular phase. We concluded that luteal phase cysts are more benign than follicular phase cysts, and it is possible that they represent an enlargement of pre-existing corpora lutea.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140993     DOI: 10.1016/s0015-0282(16)53592-4

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  Ovarian activity during follicular-phase down regulation in in vitro fertilization is associated with advanced maternal age and a high recurrence rate in subsequent cycles.

Authors:  D R Session; A H Saad; D D Salmansohn; A C Kelly
Journal:  J Assist Reprod Genet       Date:  1995-05       Impact factor: 3.412

Review 2.  Strong Evidences of the Ovarian Carcinoma Risk in Women after IVF Treatment: A Review Article.

Authors:  Dariush D Farhud; Shaghayegh Zokaei; Mohammad Keykhaei; Marjan Zarif Yeganeh
Journal:  Iran J Public Health       Date:  2019-12       Impact factor: 1.429

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.